PSMA Targeting Ligand Compound for Prostate Cancer Diagnosis and Treatment

Fri, 17 Apr 2026 23:23:51 +0000
Intellectual Property

The European Patent Office published patent application EP4431503A1 filed by Chengdu StarRay Therapeutics Co., Ltd. covering ligand compounds that target PSMA (Prostate-Specific Membrane Antigen) for use in prostate cancer diagnosis and treatment. The application includes claims for chelate compounds and their therapeutic and diagnostic applications. The patent is classified under IPC codes C07D 401/12, C07F 5/00, A61K 51/04, and A61P 35/00, covering 37 designated contracting states.